1. The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil
- Author
-
Isidori, Andrea, Giovanni, Corona, Antonio, Aversa, Gianfrilli, Daniele, Jannini, Emmanuele A., Carlo, Foresta, Mario, Maggi, Lenzi, Andrea, Andò, S, Angelletti, G, Matteo, B, Balercia, G, Giuseppe, B, Calogero, A, Canale, D, Caprio, M, Caretta, N, Erennio, C, Colpi, G, Fabbri, A, Fornengo, R, Francavilla, S, Francomano, D, Gavioli, S, Angelo, G, Giannetta, E, Goglia, U, Nicola, I, La Vignera, S, Lemma, A, Mancini, M, Manieri, C, Mansani, R, Tommaso, M, Minuto, F, Alessandro, O, Paggi, F, Rosario, P, Fiore, P, Anna, P, Perrini, S, Riccardo, P, Pozza, C, Sbardella, E, Stefano, S, and Sinisi, A.
- Subjects
Gerontology ,medicine.medical_specialty ,Article Subject ,Coronary-heart-disease ,Endocrinology, Diabetes and Metabolism ,Population ,quality-of-life ,metabolic syndrome ,arterial stiffness ,sexual dysfunction ,general-population ,diabetic-patients ,blood-pressure ,pulse pressure ,cardiovascular-disease ,SIAMS-ED ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Cardiometabolic and hormonal impairment ,Settore MED/13 - Endocrinologia ,Endocrinology ,Sexual medicine ,Internal medicine ,medicine ,Erectile dysfunction ,education ,Adverse effect ,education.field_of_study ,lcsh:RC648-665 ,Endocrine and Autonomic Systems ,business.industry ,medicine.disease ,erectile dysfunction ,PDE5 inhibitors ,Pulse pressure ,medicine.anatomical_structure ,Vardenafil ,Clinical Study ,Vascular resistance ,Metabolic syndrome ,business ,medicine.drug - Abstract
Increased cardiovascular risk has been associated with reduced response to proerectile drugs. The Italian Society of Andrology and Sexual Medicine (SIAMS) promoted an independent, multicenter study performed in 604 men (55 ± 12 yrs) suffering from erectile dysfunction (ED) to assess multiple health outcomes and response to 6-month vardenafil challenge in a real-life setting. Overall, 30.8% men had metabolic syndrome. Cardiovascular risk stratification revealed a greater number of ED subjects with moderate risk of a major adverse cardiovascular event than the general population (P<0.01). Age-adjusted pulse pressure was positively correlated with ED severity and negatively with androgens and waist circumference (P<0.01). A decline in total testosterone was observed with increasing arterial pulse pressure (P<0.05), which was not accompanied by compensatory LH rise. Follow-up on 185 men treated with vardenafil in an nonrandomized, open, single-arm trial documented a significant rise in IIEF-5 (delta = 6.1 ± 4.8) that was maintained in men with high cardiovascular risk. Mild adverse events occurred in
- Published
- 2014